Abstract:
Inadequate bowel preparation is common despite various preprocedure interventions. There is a need for an intervention at the time of colonoscopy to combat poor preparation. In this retrospective, observational study of 46 patients, we evaluated the clinical efficacy and feasibility of implementing the third generation of the Pure-Vu EVS System, a US Food and Drug Administration-cleared over-the-scope-based intraprocedural cleansing device, into our practice at the Minneapolis VA Medical Center (Minneapolis, Minnesota, United States). To study clinical efficacy, we measured bowel preparation adequacy before and after using the device, as measured by the Boston Bowel Preparation Score, and reviewed colonoscopy surveillance interval recommendations. Technical success and feasibility of using the device were measured by procedure success rates and duration. We found that BBPS scores increased from 4.4 to 7.9 when using the device. Technical success was achieved 78.3% of the time (36/46 cases). Median colonoscopy duration was 46 minutes, although there was a trend toward shorter procedures over time. This is the first clinical evaluation of the third generation of an intraprocedural cleansing device. We found the device efficacious and easy to use with low procedure failure rates, but it does come with a learning curve. We suspect that adoption of this device mutually will benefit patients and health systems with the potential to improve resource utilization.
摘要:
尽管有各种术前干预措施,但肠道准备不足仍然很常见。需要在结肠镜检查时进行干预以对抗不良的准备。在这次回顾中,46例患者的观察性研究,我们评估了实施第三代Pure-VuEVS系统的临床疗效和可行性,美国食品和药物管理局批准的基于超范围的程序内清洁装置,在明尼阿波利斯VA医学中心(明尼阿波利斯,明尼苏达,美国)。为了研究临床疗效,我们在使用该设备之前和之后测量了肠道准备的充分性,根据波士顿肠道准备评分,并回顾了结肠镜检查监测间隔建议。通过手术成功率和持续时间来衡量使用该设备的技术成功和可行性。我们发现使用该设备时,BBPS得分从4.4增加到7.9。技术成功率为78.3%(36/46例)。结肠镜检查的中位持续时间为46分钟,尽管随着时间的推移,程序有缩短的趋势。这是第三代术中清洁装置的首次临床评估。我们发现该设备有效且易于使用,程序故障率低,但它确实有一个学习曲线。我们怀疑采用该设备将使患者和卫生系统相互受益,并有可能提高资源利用率。